drugset
drugset / Trial / NCT06367738

Investigating the Persisting Effects of a Single Dose of Psilocybin on Structural Plasticity in Healthy Older Adults

NCT06367738 ↗

Phase 1 Recruiting 40 enrolled University of California, Berkeley
RandomizedSingle-groupTriple-blindBasic science

Summary

Participants in this study will undergo a series of non-invasive tests and activities designed to understand how a single dose of psilocybin might influence cognition and emotional well-being in healthy older adults. After providing written informed consent, eligible participants, aged between 60 and 85, will be randomly assigned to receive a dose of psilocybin ranging from a microdose to a moderate-to-high dose. Anatomical magnetic resonance imaging (MRI) and diffusion weighted imaging (DWI) will be used to assess changes in brain structure, while functional magnetic resonance imaging (fMRI) will be used to quantify changes in functional brain activity.

Timeline

Start
2025-11
Primary completion
2026-12-30
Completion
2027-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Psilocybin Other / unclassified 1 mg —
Subject Psilocybin Other / unclassified 10 mg —
Subject Psilocybin Other / unclassified 11 mg —
Subject Psilocybin Other / unclassified 20 mg —
Subject Psilocybin Other / unclassified 21 mg —
Subject Psilocybin Other / unclassified 30 mg —

Indications

No indication recorded.